Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

III

Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Colorado, Georgia, Maine, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

II

Advanced solid tumors and granulosa cell ovarian cancer (in expansion)

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
methoxyamine	TRC102	Base excision repair inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent

II

Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Connecticut, Massachusetts, Ohio, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
AZD6738		ATR kinase inhibitor
Capivasertib	Akt inhibitor AZD5363	pan-AKT inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Recurrent ovarian cancer

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

California, Georgia, New York, Oregon, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
DPX-Survivac	survivin antigen vaccine DPX-Survivac	Immune response against cancer expressing survivin
Epacadostat	3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360	Inhibits IDO1 to stimulate immune response

II

Advanced solid tumors

An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity

A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Alpha-DC1 vaccine		Anti-tumor immune response
Celecoxib	Celebrex
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent

II

Recurrent ovarian cancer with germline BRCA1/2 mutations

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer

Florida, New Mexico, Ohio, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

II

Advanced solid tumors with lesion treatable with radiotherapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Recurrent or persistent endometrioid/clear cell ovarian cancer

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma

Illinois, Rhode Island

Drug(s) in Trial	Other Drug Names	Main Known Action
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438	EZH2 histone methyltransferase inhibitor

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

New Jersey

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Recurrent ovarian cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
AZD6738		ATR kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

California, Maryland, New York, Ohio, Oregon, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Michigan, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Recurrent ovarian cancer (PD on or after prior PARP inhibitor)

A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition

Massachusetts, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response

II

Recurrent ovarian cancer with high MSI

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

California, Massachusetts, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with limited progression on checkpoint inhibitor treatment

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

New Jersey, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

California, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Letrozole	Femara	Aromatase inhibitor
Ribociclib	Kisqali, LEE011, CDK4/6 Inhibitor LEE011, Kisqali	CDK4/6 inhibitor

II

Advanced BRCA WT solid tumors with DNA repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

California, Kentucky, Massachusetts, Michigan, Nebraska, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Advanced solid tumors with POLE and/or POLD1 mutations

A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Epithelial ovarian cancer (with tumor lesions < 5 cm)

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
DPX-Survivac	survivin antigen vaccine DPX-Survivac	Immune response against cancer expressing survivin
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Recurrent ovarian cancer

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
2X-121		PARP inhibitor

II

Advanced solid tumors with prior PD-1/PD-L1 targeted treatment

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

California

Drug(s) in Trial	Other Drug Names	Main Known Action
BI 754091	anti-PD-1 monoclonal antibody BI 754091	Blocks PD-L1/2 inhibition of T cells
BI 754111		Blocks LAG-3 inhibition of T cells

Ib/II

Platinum sensitive epithelial ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies)

A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alabama, Alaska, Arkansas, California, Connecticut, Georgia, Maine, Massachusetts, Michigan, New Jersey, New York, Oklahoma, Rhode Island, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

Ib/II

Advanced solid tumors

An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

California, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted kinase inhibitor

Ib/II

Platinum sensitive recurrent ovarian cancer

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

Arkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor

Ib/II

Advanced FRalpha+ ovarian cancer

A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Massachusetts, Ohio, Oklahoma, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Mirvetuximab Soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)

Ib

Advanced solid tumors

A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

California, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
NHS-IL12	M9241, immunocytokine NHS-IL12	IL-12 receptor agonist

Ib

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Galunisertib	LY2157299	TGFBR1 antagonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

Ib

Advanced solid tumors

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
TSR-022		Blocks TIM-3 inhibition of T cells
TSR-042	ANB011, anti-PD-1 monoclonal antibody TSR-042	Blocks PD-L1/2 inhibition of T cells

Ib

Recurrent or persistent ovarian cancer

Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin

Florida, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Oregovomab	OvaRex, Monoclonal Antibody B43.13, B43.13	Immune response against cancer expressing CA125
poly ICLC	poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC	Activates dendritic cells and induces interferon production

Ib

Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)

Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Irinotecan	Camptosar, Campto, Campothecin-11	Topoisomerase I inhibitor
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

Ib

Platinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

Arizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Cobimetinib	Cotellic, GDC-0973, XL518	MEK1 inhibitor
Niraparib	MK4827, Zejula	PARP inhibitor

Ib

Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2 WT)(inc expansion)

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Niraparib	MK4827, Zejula	PARP inhibitor

Ib

Advanced solid tumors (inc expansion)

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

California, Illinois, North Carolina, Pennsylvania, Texas, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Epacadostat	3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360	Inhibits IDO1 to stimulate immune response
INCB050465	PI3K-delta inhibitor INCB050465	PI3K delta inhibitor
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells

Ib

Platinum sensitive or partially sensitive ovarian cancer

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

New Jersey

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism

Ia/Ib

Advanced solid tumors (in ovarian expansion)

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Arizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
FPA150	anti-B7-H4 monoclonal antibody FPA150	blocks B7-H4 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ia/Ib

Advanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

District of Columbia

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor

I/IIa

Advanced solid tumors

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

New Jersey, New York, Pennsylvania, Utah

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986207	anti-TIGIT monoclonal antibody BMS-986207	Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Platinum sensitive ovarian cancer at first or second recurrence

Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

Arizona, Florida, Kentucky, Minnesota, Pennsylvania, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor

I/II

Recurrent ovarian cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Cediranib	Recentin, Cediranib maleate, AZD2171	VEGFR1-3 kinase inhibitor
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor

I/II

Extrapulmonary small cell ovarian cancer

A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Topotecan	Hycamptamine, Hycamtin, TOPO	Topoisomerase I inhibitor

I/II

Platinum sensitive recurrent ovarian cancer

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

Georgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor

I/II

Recurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancer

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Massachusetts, New Jersey, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986226	anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226	Stimulates ICOS to increase T cell activity and immune response
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
LOXO-292	RET kinase inhibitor LOXO-292	RET-kinase inhibitor

I/II

Advanced solid tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

California, Connecticut, New Jersey, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
NC318

I/II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Rintatolimod	Atvogen, Ampligen	TLR-3 agonist and immune cell stimulator

I/II

Advanced solid tumors

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Colorado, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
BGB-A425		Blocks TIM-3 inhibition of T cells
Tislelizumab	anti-PD-1 monoclonal antibody BGB-A317	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors

California, Colorado, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986258	anti-TIM3 antibody BMS-986258	Blocks TIM-3 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Colorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986249	Probody of ipilumumab	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapy

A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Florida, Oklahoma, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
EDP1503	monoclonal microbial EDP1503
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Recurrent or persistent WT1+ ovarian cancer

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

California, Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Galinpepimut-S		Immune response against cancer expressing WT1
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Michigan, North Carolina, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells
MGC018	A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload	ADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin)

I/Ib

Platinum sensitive recurrent ovarian cancer (at least 2 prior platinum therapies)

A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Arizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Pamiparib	PARP inhibitor BGB-290	PARP inhibitor
Tislelizumab	anti-PD-1 monoclonal antibody BGB-A317	Blocks PD-L1/2 inhibition of T cells

I/Ib

Advanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification)

Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes

Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Veliparib	ABT-888	PARP inhibitor

I

Advanced ovarian cancer (no prior PARPi)

A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer

South Dakota

Drug(s) in Trial	Other Drug Names	Main Known Action
Everolimus	Zortress, RAD001, Certican, Afinitor	mTOR inhibitor
Niraparib	MK4827, Zejula	PARP inhibitor

I

Recurrent or refractory ovarian cancer

A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Decitabine	5-aza-dCyd, deoxyazacytidine, dezocitidine, Dacogen	DNA methylation inhibitor
Genetically Engineered NY-ESO-1-specific T Lymphocytes		Immune response against cancer expressing NY-ESO-1

I

Advanced solid tumors

A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors

California, Colorado, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
IL-12	cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12	IL-12 receptor agonist
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors (in expansion)

A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors

Illinois, New Mexico, Ohio, Pennsylvania, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
TRX518	anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518	GITR (glucocorticoid-induced TNFR) agonist

I

Advanced solid tumors (in expansion)

Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
TRX518	anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518	GITR (glucocorticoid-induced TNFR) agonist

I

Advanced solid tumors

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

Arizona, California, Colorado, Connecticut, District of Columbia, Massachusetts, Nevada, New York, Oklahoma, Oregon, Pennsylvania, Tennessee, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
RO7198457	personalized cancer vaccine RO7198457, PCV RO7198457	Immune response against tumor-associated antigens

I

Recurrent advanced ovarian cancer (disease only in abdomen/pelvis)

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
NK100	NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100	Anti-tumor immune response

I

Advanced solid tumors with AKT1, AKT2, or AKT3 mutations

A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3

New Jersey, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Capivasertib	Akt inhibitor AZD5363	pan-AKT inhibitor

I

Advanced solid tumors (inc expansion)

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maine, Massachusetts, Michigan, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
TSR-042	ANB011, anti-PD-1 monoclonal antibody TSR-042	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors including those with BRCA mutations (in expansion)

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	CDK1, 2, 5, 9 inhibitor
Veliparib	ABT-888	PARP inhibitor

I

Recurrent ovarian cancer

A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
COTI-2	mutant p53 activator COTI-2	Mutant p53 activator

I

Recurrent or persistent ovarian cancer

Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Prolanta		Prolactin receptor antagonist

I

Advanced solid tumors including those with BRCA mutations

A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors

New Jersey, Ohio, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Talazoparib	Talazoparib Tosylate, BMN-673, MDV3800	PARP inhibitor

I

Advanced solid tumors (in ovarian expansion)

Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors

Ohio

Drug(s) in Trial	Other Drug Names	Main Known Action
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine		Immune response against cancer expressing HER2

I

MUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies)

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes	4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes	Immune response against cancer expressing CA125
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor

I

Advanced solid tumors with CDKN2A deletion (inc expansion)

A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP

Connecticut, Massachusetts, New York, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
AG-270		methionine adenosyltransferase 2a (MAT2A) inhibitor

I

Advanced solid tumors (inc expansion)

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

California, New Jersey, North Carolina, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
INCAGN02385		Blocks LAG-3 inhibition of T cells

I

Advanced solid tumors (in ovarian expansion)

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Alabama, Arizona, California, Illinois, Massachusetts, New York, Oklahoma, Rhode Island, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
SY-1365	SY 1365, CDK7 inhibitor SY-1365	CDK7 inihibitor

I

Advanced solid tumors with FGFR over-expression

A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors

California, Illinois, Maryland, Massachusetts, Michigan, Nevada, New York, South Carolina, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Rogaratinib	pan-FGFR tyrosine kinase inhibitor BAY1163877, BAY1163877	pan-FGFR kinase inhibitor

I

Advanced HER+ solid tumors

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression

Missouri

Drug(s) in Trial	Other Drug Names	Main Known Action
ARX788	anti-HER2 antibody-drug conjugate ARX788, ADC ARX788	ADC: anti-HER2 + microtubule destabilizer (MMAF)

I

Advanced HER2+ solid tumors (inc expansion)

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

California, District of Columbia, Maryland, New York, Pennsylvania, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
PRS-343	anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343	Immune response against cancer expressing HER2

I

Recurrent or persistent FRalpha+ high grade serous ovarian cancer

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
MOv19-BBz CAR T		Immune response against cancer expressing folate receptor

I

Advanced solid tumors (inc expansion)

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Florida, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
BDB001		TLR agonist and immune cell stimulator
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I

Recurrent advanced serous ovarian cancer

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Alabama, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
INCB062079		FGFR4 inhibitor

I

Advanced solid tumors (inc expansion)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors

Arizona, Michigan, New Jersey, North Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells

I

Recurrent ovarian cancer

A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Eribulin	B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog	Tubulin polymerization inhibitor

I

Advanced solid tumors (amenable to radiation treatment)

Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

Illinois

Drug(s) in Trial	Other Drug Names	Main Known Action
Cabiralizumab	anti-CSF1R monoclonal antibody FPA008, FPA008	CSF1R antagonist and tumor-associated macrophage inhibitor
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Urelumab	BMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibody	Stimulates 4-1BB (CD137) to increase T cells and immune response

I

Advanced MAGE-A3/A6+, HLA-DPB1*04:01+ (inc expansion)

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

California, Florida, Massachusetts, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
KITE-718	MAGEA3/A6-targeted TCR-transduced T cells KITE-718, autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718	immune response against cancer expressing MAGE-A3/A6

I

Advanced ovarian cancer (inc expansion)

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies

Colorado, Maryland, Nevada, North Carolina, Oregon, Texas, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
AB928	AB928, a dual antagonist of the A2aR and A2bR adenosine receptors	Blocks adenosine A2A/B receptors inhibition of T cells
Liposomal doxorubicin	Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	Topoisomerase II inhibitor

I

Recurrent or refractory NY-ESO-1+ epithelial ovarian cancer

A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)		Immune response against cancer expressing NY-ESO-1
NY-ESO-1 CD8-TCR Engineered T Cells		Immune response against cancer expressing NY-ESO-1

I

Advanced solid tumors

A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors

Georgia, Illinois, Michigan, South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Pevonedistat	NAE inhibitor MLN4924, Nedd8-activating enzyme inhibitor MLN4924	NAE inhibitor

I

Advanced solid tumors

Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas

Maryland, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Copanlisib	BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I

Recurrent high grade ovarian cancer

Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
IL-21-Primed CD8+ Tumor Antigen-Specific T Cells	adoptively transferred central memory-type CTL targeting ovarian cancer antigens	Immune response against cancer expressing PRAME and/or COL6A3
Utomilumab	PF-05082566	Stimulates 4-1BB (CD137) to increase T cells and immune response

I

Advanced solid tumors

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
ASTX727	CDA inhibitor E7727/decitabine combination agent ASTX727	DNA methylation inhibitor

I

Advanced solid tumors

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

Connecticut, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
ABBV-151		Undisclosed mechanism
ABBV-181	anti-PD1 monoclonal antibody ABBV-181	Blocks PD-L1 inhibition of T cells

I

Advanced solid tumors

Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]

California

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986178	anti-OX40 antibody BMS 986178	Stimulates OX40 to increase T cell activation and immune response
SD-101	TLR9 agonist SD-101, ISS-ODN SD-101	TLR9 agonist and immune cell activator

I

Advanced solid tumors

A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors

Florida, Illinois, New York, Oklahoma, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
M3814	DNA-PK inhibitor MSC2490484A	DNA-PK inhibitor

I

Advanced solid tumors that are TP53 WT

A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
ALRN-6924	MDM2/MDMX inhibitor ALRN-6924	MDM2 and MDMX inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

I

Advanced solid tumors (in expansion)

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors

Arizona

Drug(s) in Trial	Other Drug Names	Main Known Action
TRK-950	monoclonal antibody TRK-950	Undisclosed mechanism

I

Advanced solid tumors (inc expansion)

A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
IPN60090		Undisclosed mechanism
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

Alabama, California, Connecticut, North Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
ABBV-368		Stimulates OX40 to increase T cell activation and immune response
ABBV-927	anti-CD40 agonist monoclonal antibody ABBV-927	Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response

I

Advanced solid tumors (inc expansion)

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

North Carolina, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
AB122		Blocks PD-L1 inhibition of T cells
AB154		Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells

I

Recurrent ovarian cancer

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

I

Advanced solid tumors (inc expansion)

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

California, Minnesota, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
FT500		Anti-tumor immune response
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors (inc expansion)

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

California

Drug(s) in Trial	Other Drug Names	Main Known Action
VMD-928	TrkA inhibitor VMD-928	TRK kinase inhibitor